For the 2017 influenza season, the following quadrivalent influenza vaccine will be registered and available for use in children from 6 months to 35 months (less than 3 years):
Sanofi-Aventis – FluQuadri Junior
From the age of 3 years
For the 2017 influenza season, in addition to the quadrivalent vaccines mentioned above, the following quadrivalent influenza vaccines will be registered and available for use in children from the age of 3 years:
GlaxoSmithKline – Fluarix Tetra
Sanofi-Aventis – FluQuadri
Vaccine strains for 2017
Following a review of the strains of influenza that were circulating in Australia and the Southern Hemisphere in the winter of 2016, the Australian Influenza Vaccine Committee (AIVC) recommended that the TGA should adopt the September 2016 World Health Organization (WHO) recommendations for the strains to be covered by the 2017 seasonal influenza vaccines. Details of the strains were announced on the TGA website on 25 October 2016.
This year, only quadrivalent vaccines will be available. Quadrivalent vaccines include two influenza A strains and two B strains.
Reporting of adverse events following influenza vaccine
Health professionals and consumers are encouraged to report all adverse events associated with influenza vaccination in patients of any age to the TGA or through the current arrangements in their State or Territory.
All reports contribute to the TGA's ongoing monitoring of the safety of influenza vaccines.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a vaccine or medicine.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.